Big Money Sentiment decreased to 0.99 in 2018 Q4. It has change of 0.34, from 2018Q3’s 1.33. The ratio turned negative due to Neurocrine Biosciences, Inc. positioning: 57 sold and 87 reduced. 55 funds took positions and 87 increased positions. Investors holded 86.00 million in 2018Q3 but now own 86.79 million shares or 0.91% more.
Comerica Bancshares has invested 0.01% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Sterling Strategies Ltd Llc reported 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). D E Shaw & Inc invested 0.02% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Vident Advisory Lc invested in 0.02% or 4,460 shs. Dimensional Fund L P stated it has 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Capital Guardian Trust Company holds 495,582 shs. Renaissance Technology Ltd Liability has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Massachusetts Fin Ma stated it has 101,658 shs or 0% of all its holdings. M&T National Bank & Trust Corp has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Numerixs Technology has 0.07% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 3,300 shs. Glenmede Trust Na invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Northern Corporation has invested 0.01% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Rock Springs Cap Management Ltd Partnership owns 788,600 shs for 2.66% of their capital. Suntrust Banks holds 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 24,311 shs. Fosun Limited invested in 62,323 shs.

Neurocrine Biosciences, Inc. had 24 insider sales and 0 buys since October 29, 2018. This’s net activity of $15.26 million. $156,159 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shs were sold by ROBERTS EIRY. On Monday, December 3 1,178 shs were sold by ABERNETHY MATT, worth $106,020. 15,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shs with value of $1.72M were sold by LYONS GARY A. POPS RICHARD F sold $425,893 worth of stock or 4,123 shs. The insider Gano Kyle sold $63,673. 920 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shs with value of $76,859 were sold by Bozigian Haig P..

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

A total of 10 analysts rate Neurocrine Biosciences (NASDAQ:NBIX) as follows: 7 “Buy”, 3 “Hold” and 0 “Sell”. Тherefore 70% are bullish. (NASDAQ:NBIX) has 11 ratings reports on Mar 14, 2019 according to StockzIntelligence. On Tuesday, March 12 the stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given by Cantor Fitzgerald. On Tuesday, November 6 the firm has “Overweight” rating given by Morgan Stanley. On Thursday, January 24 the rating was downgraded by Needham to “Hold”. On Thursday, September 20 the rating was maintained by Stifel Nicolaus with “Buy”. On Wednesday, March 13 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, March 13 the company was maintained by Cowen & Co. On Wednesday, January 23 JP Morgan downgraded Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating. JP Morgan has “Neutral” rating and $100 target. On Tuesday, March 12 Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating. Leerink Swann has “Hold” rating and $87 target. Listed here are Neurocrine Biosciences, Inc. (NASDAQ:NBIX) PTs and latest ratings.

13/03/2019 Broker: Cowen & Co Rating: Buy New Target: $105 Maintain
13/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $102 Maintain
12/03/2019 Broker: Leerink Swann Rating: Hold New Target: $87 Maintain
12/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $127 Maintain
24/01/2019 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade
23/01/2019 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Old Target: $97 New Target: $100 Downgrade
13/12/2018 Broker: Goldman Sachs Rating: Buy New Target: $103 Initiates Coverage On
21/11/2018 Broker: Canaccord Genuity Rating: Buy New Target: $111 Initiates Coverage On
13/11/2018 Broker: Leerink Swann Rating: Market Perform New Target: $110 Initiates Coverage On
06/11/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $145 New Target: $135 Maintain

NBIX is reaching $83.25 during the last trading session, after decreased 0.81%.Neurocrine Biosciences, Inc. has volume of 191,318 shares. Since March 14, 2018 NBIX has declined 6.23% and is downtrending. The stock underperformed the S&P 500 by 10.60%.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally.The firm is worth $7.56 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease.The P/E ratio is 378.41. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

For more Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news released recently go to: Bizjournals.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Voyager Therapeutics stock jumps on 2nd Parkinson’s deal – Boston Business Journal” released on February 22, 2019, “Neurocrine Biosciences: This Is Only The Beginning – Seeking Alpha” on August 24, 2018, “Notable Wednesday Option Activity: NBIX, AZO, RNET – Nasdaq” with a publish date: November 14, 2018, “Neurocrine Biosciences May Have Something Interesting With NBI-74788 – Seeking Alpha” and the last “Neurocrine Biosciences +6% on 2019 outlook – Seeking Alpha” with publication date: January 07, 2019.